Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 68Lung Neoplasms 12Adenocarcinoma 3Pancreatic Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Neoplasms 2NSCLC 2Melanoma 2Colorectal Neoplasms 2Breast Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1NSCLC Harboring NRG1 Fusion 1

Interventions

Carboplatin 12Pemetrexed 11pembrolizumab 10Paclitaxel 6Cisplatin 6Erlotinib Hydrochloride 5Docetaxel 5Nivolumab 4Gefitinib 4spartalizumab 3osimertinib 3Gemcitabine 3EC145 3Crizotinib 3Afatinib 3technetium 99m etarfolatide 2pralsetinib 2fludarabine 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2aldesleukin 2Vinorelbine 2Radiotherapy 2Quality of Life 2MORAb-202 2Immunotherapy 2Drug Therapy 2Cyclophosphamide 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × Afatinib × Thoracic × Clear all
NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Boehringer Ingelheim

Phase 3 Completed
364 enrolled 28 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Boehringer Ingelheim

Phase 3 Completed
345 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡